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Comparison of Immune Reactivity to Respiratory Challenges in Asthmatics  





Asthma and panic disorder (PD) are highly comorbid conditions. The objective of this study was 
to examine if PD altered immune reactivity in asthmatics to two acute respiratory stress 
challenges. We hypothesized that asthmatics with PD would have increased proportions of 
sputum eosinophils compared to asthmatics without PD in reaction to both challenges. 
Methods 
Eleven participants (7 PD, 4 non-PD) inhaled methacholine (which produces an asthma attack) 
on a first day, and on a second, two gases in randomized order: compressed air and a 35% carbon 
dioxide (CO2) solution (the latter produces a ‘simulated’ panic attack). Following each challenge, 
we induced sputum to assess immune cell profiles. 
Results 
ANCOVA-like GLMs demonstrated that the PD group had a significantly lower proportion of 
sputum lymphocytes (β=-0.75, 95% CIs = -1.30–0.20) than the non-PD group in response to 
methacholine. A trend also emerged for the PD group reacting with more eosinophils (β=5.03, 
95% CIs = -0.73–10.79). The presence of PD conferred no effect on neutrophils (β=-11.72, 95% 
CIs = -34.64–11.18) or macrophages (β=0.10, 95% CIs = -22.63–22.82). Analyses did not reveal 
a significant effect of PD on immune reactivity to CO2. 
Conclusions 
PD appears to influence immunological responses in asthmatics by decreasing the proportion of 
sputum lymphocytes following a methacholine challenge, but does not seem to alter the 
immunological responses to CO2 inhalation. Additional studies are indicated to characterize the 
immunological interrelations between these conditions; these discoveries could allow clinicians 






First and most importantly, I would like to thank my supervisor, Dr. Simon Bacon, whose 
guidance and attention over the past four years has been invaluable. Under your supervision, I 
have grown and developed myself, and your support has allowed me to aim high and to achieve. 
I have learned tremendously from you, and hope to continue learning from you in the future. 
Thank you for being an exceptional supervisor! 
I would also like to thank the other members of my thesis committee, Dr. Peter 
Darlington and Dr. Kim Lavoie, with whom I have had many stimulating conversations and who 
have provided countless insights from their respective fields of expertise for this project. 
I would like to recognize the Canadian Institutes of Health Research (CIHR), Concordia 
University, and the Montreal Behavioural Medicine Centre for supporting me financially through 
this project with Master’s training scholarships. 
I would like to recognize the contributions of my colleagues at the Hôpital du Sacré-
Coeur de Montréal: Guillaume, whose familiarity and exceptional capability as lab manager has 
facilitated my work on this project. Thank you for never making me feel like my questions and 
requests were bothersome, despite your overwhelming workload. Maxine, with whom I have 
worked for over two years on this project, thank you for building up this project, for taking the 
time to mentor me, and for making me feel like my efforts were both valuable and appreciated. It 
has been a pleasure to work on this project with you!  
A special thank you also to Mrs. Jocelyne L’Archevêque and Mrs. Carole Trudeau, who 
regularly made themselves available to answer countless questions, who readily made 
themselves available to see our study participants, and without whom testing would have been 
impossible.  
Finally, to my sister and to my mom, your unconditional love and support has carried me 









This study, which was a sub-study of a larger study looking to investigate the impact of 
stress on cardiac and bronchial reactivity in asthmatics, sought to explore the nature of immune 
reactivity to stress in asthma. This document consists of three parts: 
1) Review of the Literature 
2) Manuscript prepared for submission to Psychosomatic Medicine 
3) Appendices 
The document has been prepared for submission to Psychosomatic Medicine primarily 
due to the appropriateness of the content for the journal. In addition, our laboratory has 
submitted articles to this journal and has consistently had them published. Finally, I have also 
had a good deal of success personally with submitting abstracts to the organization of the 
journal’s international conference: of the two abstracts I submitted to the American 
Psychosomatic Society’s Annual International Conference, one was accepted to be presented as a 
part of an oral symposium, and the second was accepted to be presented at a poster session.  
Though Psychosomatic Medicine requires a numbered referencing style and page 
numbers that begin at the start of the manuscript, this document will have numbering start on this 
page and will have the first reference in the Review of the Literature; a single aggregated list of 
references will be found at the end of the manuscript, rather than having a different list of 
references for each section.  
All authors participated in the development of the protocol. I generated the main idea for 
this project, am the main author of the text, developed the database, and assisted with data 
collection, entry, processing, and analysis. Patient recruitment was conducted by myself and 
Maxine Boudreau. She, as well as Drs. Kim L. Lavoie and Simon L. Bacon, conceptualized the 
main study that this present study is a sub-study of, regularly helped me with this project, and 
were available to take questions and for consultation. Dr. Simon L. Bacon also carried out the 
statistical analyses used in this article. 
With regards to the protocol itself, the methacholine challenge was administered by a 
laboratory technician employed by the Hôpital du Sacré-Coeur de Montréal who had over 20 
years of experience conducting this test, while physiological data and questionnaire data were 
initially recorded by Maxine Boudreau, and then by me. On the second day of tests, the panic 
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induction protocol was executed by three individuals: one laboratory technician who handled the 
metabolic cart and ventilatory maneuvers, Maxine Boudreau administered psychological 
questionnaires and determined if the participant had experienced a panic attack, and I 
manipulated the mask, oversaw the data collection by certain pieces of equipment, and 
administered the gas mixtures. Collecting sputum samples on all three days as well as the cell 
count analyses were handled by a laboratory technician employed by the hospital who had over 
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REVIEW OF THE LITERATURE 
 
Asthma 
Asthma is a complex respiratory disorder, characterized by reversible and intermittent 
airway obstruction, inflammation, and hyper-reactivity, that affects over 8% of Canadians over 
the age of 12 (1). Airway obstruction in asthma is the result of two overlapping processes (2): 
first, inflammation in the airways causes the formation of mucus, producing a physical 
obstruction in the airway lumen, and second, if inflammation remains untreated, the smooth 
muscles that surround the airway become sensitive and contract; this is called 
“bronchoconstriction.” Aside from also contributing to airway narrowing, bronchoconstriction 
also produces the common symptoms of asthma: shortness of breath, wheezing, bouts of 
coughing, and feelings of tightness in the chest (3). 
While it typically develops in childhood and progresses into adulthood, asthma can 
develop at any age (4) and its symptoms can vary dramatically between exacerbations or from 
one person to another (2). Several factors, such as genetics (5) and exposure to occupational 
allergens (6), have been shown to play a role in the development of asthma, but the number of 
asthma phenotypes makes the outlining of exact pathogenic mechanisms difficult (3). Asthma is, 
however, recognized as an immunological disease, and efforts have been made to identify the 
interactions between leukocytes and cytokines that modulate the disease process in asthma (7).  
From an immunological point of view, cytokines are recognized as playing a critical role 
in the chronic inflammation process of asthma (8). In mild to moderate asthma, a T helper type 2 
cell (Th2) cytokine profile dominates over a Th1 profile (9); the Th2 cytokines (such as 
interleukin(IL)-4 and IL-13) reciprocally inhibit the ability of Th1 cells to produce their own 
cytokines (including interferon(IFN)-γ and IL-12). Among the Th2 cytokines, eotaxin and IL-5 
serve as two important chemoattractants for eosinophils, which promote the infiltration of 
eosinophils into the lung and contribute to their maturation; lung eosinophilia is one of the 
hallmarks of allergic asthma (10). Once in the lung, eosinophils become resilient to apoptosis 
(10), and begin releasing their cytotoxic granules, including proteins such as eosinophilic 
cationic protein and eosinophil peroxidase (11), some of which contribute to the destruction of 
the airway epithelium that is typical in asthma (12). In addition, eosinophils release Th2-
promoting and Th1-suppressing cytokines and chemokines, such as IL-5 and monocyte 
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chemotactic protein-1 (7, 13), thus further propagating inflammation in a positive feedback loop 
style. Unfortunately, due to the nature of cytokines serving many functions and having many 
different effects, identifying their involvement in asthma’s pathophysiology may be insufficient, 
but is nonetheless an important step in understanding the disease’s mechanisms.  
Despite the advancements in outlining pathogenic processes in asthma and the 
development of a multiplicity of asthma medications, asthma control continues to be a problem 
in Canada. Data from the 2003 Canadian Community Health Survey indicated that more than 
half of affected Canadians reported having had an asthma attack or having been affected in their 
daily activities by asthma symptoms in the past 12 months, despite over 65% of these people 
reporting taking medication (14). More recently, a study noted that 82% of 418 patients who had 
controlled asthma had times in the previous year where their symptoms became worse. The study 
also cited that there had been no improvement in asthma control among Canadians since 1999 
(15). These figures suggest that factors other than pharmacological treatment may be at play. 
 
Psychological Factors in Asthma 
Recently, researchers have turned to exploring the realm of health psychology in an effort 
to explain the continued inability of many asthmatics to keep their asthma under control. 
Psychiatric disorders are overrepresented in asthmatic populations (16-21). In addition, 
psychological factors such as stress and anxiety can have a significant influence on respiratory 
functioning, and have been linked to worse outcomes in asthmatics: anxiety disorders have a 
negative effect on asthma-related quality of life (22, 23) and asthma control (24). Since the 
majority of studies assessing the link between psychological factors and asthma have been 
correlational and limited to examining primarily self-reported outcomes (e.g., asthma control and 
quality of life), the mechanisms driving the relationship between anxiety and worse asthma 
remain elusive. In non-asthma patients there are a number of studies which depict a model where 
an interaction between acute stress and chronic stress mediates immunological pathways (25). 
Despite the limited literature, the model appears to hold true in the context of asthma, as well 
(26-28). Physiologically, acute stress is thought to trigger immune reactivity in individuals to 
protect them during this period of stress. Meanwhile, chronic stress, which has been shown to 
suppress Th1 immunity, may be driving and amplifying inflammatory reactions in individuals 
affected by inflammatory conditions such as asthma, where a Th2 immune profile exists (25). 
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The model would suggest that the occurrence of an acute stress may exacerbate the chronic 
stress-amplified immune processes present in asthma, thus worsening the condition or producing 
negative effects. Despite the emergence of this model, a recent review had a very small pool of 
research to draw from when discussing the immune system’s role in asthma and different types 
of psychological distress (29). Given that anxiety is pervasive in asthma (some studies report that 
up to 52% of asthmatics suffer from at least one anxiety disorder (17, 20, 22)), an anxiety 
disorder which entails both chronic stress and bouts of acute stress would be well-suited in the 
investigation of this paradigm within the context of asthma. 
Recently, the association between asthma outcomes and anxiety sensitivity, a type of trait 
anxiety defined as fear of physical and psychological anxiety symptoms (30), has been 
examined. Studies found that patients with more elevated fear of physical symptoms also had 
worse asthma control and quality of life (31, 32). Interestingly, anxiety sensitivity was, for a 
cohort of university students, found to be the strongest predictor of the development of panic 
symptoms and panic attacks (33).  
 
Panic Disorder 
 Panic disorder (PD) is a recognized anxiety disorder in the Diagnostic and Statistical 
Manual of Mental Disorders-IV (DSM-IV) that is characterized by sudden, unprovoked, and 
recurrent panic attacks (34), which are episodes of intense fear that are associated with a number 
of cognitive and physical symptoms. For a list of diagnostic criteria for PD from the DSM-IV, 
see Appendix A. 
PD is of particular interest in asthma: many studies report that PD is quite common in 
asthma, with one study reporting that 13.9% of their cohort of asthmatic patients had panic 
disorder (17); in contrast, 1.5% of the regular population is estimated to have PD (35). Like other 
anxiety disorders, PD also appears to be associated with worse outcomes in asthma. A study that 
evaluated the last 12 months of a group of asthmatic patients’ medical charts found that the 
presence of PD resulted in a significantly lower self-reported quality of life, a significantly 
greater use of short-acting asthma medication compared to the asthma only group, and 
significantly more visits to primary care physicians (36). PD may influence asthma negatively by 
virtue of panic attacks having many similar symptoms to asthma attacks (shortness of breath, 
sudden anxiety, sensations of being smothered, and fear of losing control); this overlap and the 
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catastrophization of somatic symptoms by PD patients leads them (and medical professionals) to 
occasionally misinterpret the nature of the crisis, which may delay appropriate treatment; 
however, it is also possible that panic attacks may trigger asthma attacks through physiological 
pathways (37). In fact, the unanticipated panic attacks that occur within the context of PD makes 
it fit well into our current acute and chronic stress model: could panic attacks (i.e., an acute 
stressor) make asthma worse through amplified immune reactivity? While Feldman et al. found 
that the presence of PD seemed to confer no effect on asthma severity, asthma severity was 
evaluated using spirometry, self-report asthma symptoms, and self-reported medication use 
rather than through an examination of the patients’ immunological profiles. Given that 
bronchoconstriction is the result of both immunological and parasympathetic nervous system 
components (38, 39), these findings may not truly reflect the influence of PD on immunological 
functioning in asthma.  
There exists scant literature on immunological abnormalities in PD, and results are 
contradictory. One study in non-asthma individuals by Brambilla found that PD patients had 
similar levels of tumor necrosis factor(TNF)-α to age- and sex-matched healthy controls (40). 
Another study reported that PD patients had lower IFN-γ and IL-12 as compared to healthy 
subjects (41). Given that Th1 cytokines appear to be suppressed by Th2 cytokines, we may be 
able to infer through these findings that PD may tend to favour a Th2 immune profile, similar to 
that which exists in asthma. Findings do not seem to be consistent across studies, however: 
another study found that elevated levels of IFN-γ were detectable in the serum of 75% of PD 
patients as compared to only 35% of age- and sex-matched healthy controls (42). This last study 
also had some potentially inconsistent findings: IL-4 was more detectable while IL-10 was less 
detectable in PD patients. Since both are Th2 cytokines, one might have anticipated that both 
would be more (or less) detectable together. Of note, the study also reported that eotaxin was 
significantly more detectable in patients with PD. Unfortunately, we know of no studies in which 
immunity in PD has been investigated within the context of asthma, but the abundance of Th2 
cytokine levels which are seemingly disrupted in PD are enough to suggest that the effects of PD 






The Panic Attack Phenomenon 
Unanticipated panic attacks are the hallmark of PD; as such, researchers interested in the 
physiological effects of PD would seek to investigate them. Studying PD-related panic attacks in 
a research setting is impractical given their unanticipated nature, however. To study them, 
researchers have sought and determined a number of ways to induce panic. Currently, several 
challenges and procedures exist which reliably induce a “simulated panic attack,” including 
lactate infusion (43), caffeine ingestion (44), breath-holding (45), hyperventilation (46), 
cholecystokinin tetrapeptide injection (47), and carbon dioxide (CO2) inhalation. 
 The inhalation of air containing more than 5% CO2 induces panic and anxiety in both 
healthy controls and in PD patients, though the effects have been shown to be more pronounced 
in the latter group (48, 49). CO2 has been shown to be one of the most panicogenic agents, being 
a superior stimulus for panic to both caffeine ingestion (50)  and hyperventilation of room air 
(51). In addition, panic induced by CO2 inhalation is similar to naturally occurring panic (52, 
53). Panic disorder patients are thought to be particularly susceptible to the inhalation of carbon 
dioxide as these individuals are postulated to have hypersensitive CO2 chemoreceptors, leading 
them to react to otherwise harmless concentrations of carbon dioxide. This “suffocation false 
alarm” hypothesis, first described by Klein (54), explains that the “excessive” CO2 triggers 
hyperventilation in an effort to eliminate CO2 from the body.  
Two main panic-inducing CO2 inhalation protocols are currently used in panic research. 
One involves the continuous breathing of 5% or 7% CO2 gas mixtures for a period of time until 
patients are overwhelmed with panic (which usually occurs within minutes (55)). The other 
involves a single vital capacity inhalation of a 35% CO2 and 65% oxygen gas mixture, which is 
held for a few seconds before being exhaled (53). Though both protocols have been shown to 
reliably induce panic anxiety, it seems that no study has directly examined the efficacy of one 
method over the other. One study compared the two continuous breathing CO2 mixtures and 
found that each had its advantages: the inhalation of the 7% CO2 solution allowed clinicians to 
more accurately perceive the occurrence of a panic attack, but the inhalation of the 5% CO2 
solution was better resisted by the patients; since the patients could last longer before being 
overcome with panic, the researchers could collect more physiological data (51). Another study 
had healthy participants inhale increasing concentrations of CO2 gas (0, 9, 17.5, and 35%), and 
found that participants reported higher anxiety and panic symptoms in a dose-dependent manner 
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(56). These studies illustrate that inhaling higher concentrations of CO2 gas will be more likely to 
cause a panic attack.  
Only one study was found to have evaluated immune markers in PD patients before and 
after a simulated panic attack induced by 35% CO2 inhalation. The study by van Duinen and 
colleagues reported that, while induced panic attacks caused significantly higher levels of 
anxiety in the PD patients as anticipated, the CO2 challenge did not cause any significant changes 
in the serum immune markers that were measured (IL-6, IL-8, IL-10, IL-1 receptor agonist, IFN-
γ, TNF-α, soluble IL-6 receptor, and soluble IL-2 receptor) (57). Interestingly, the study reported 
that there were no immunological differences at baseline between the PD patients and the healthy 
controls, which contrasts the findings of both Tukel et al. (41) and Hoge et al. (42), who all 
found that PD patients had different levels of many cytokines than healthy participants. 
Furthermore, given that the study by van Duinen et al. was neither carried out with asthmatics, 
nor did it examine key cells and mediators involved in the pathophysiology of asthma, one might 
wonder how applicable these findings are to an asthmatic population, and within the acute 
stress/chronic stress model altogether. 
 
The available data addressing the physiological mechanisms of how psychological 
distress negatively influences asthma is lacking and, in many cases, non-specific; the conclusions 
that can be drawn from the literature currently are speculative at best. Given the lack of data on 
the subject and the large potential for more specific treatment strategies, it becomes clear that a 
closer look at how psychological distress, specifically the presence of PD, can worsen outcomes 
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Asthma and panic disorder (PD) are highly comorbid conditions. The objective of this study was 
to examine if PD altered immune reactivity in asthmatics to two acute respiratory stress 
challenges. We hypothesized that asthmatics with PD would have increased proportions of 
sputum eosinophils compared to asthmatics without PD in reaction to both challenges. 
Methods 
Eleven participants (7 PD, 4 non-PD) inhaled methacholine (which produces an asthma attack) 
on a first day, and on a second, two gases in randomized order: compressed air and a 35% carbon 
dioxide (CO2) solution (the latter produces a ‘simulated’ panic attack). Following each challenge, 
we induced sputum to assess immune cell profiles. 
Results 
ANCOVA-like GLMs demonstrated that the PD group had a significantly lower proportion of 
sputum lymphocytes (β=-0.75, 95% CIs = -1.30–0.20) than the non-PD group in response to 
methacholine. A trend also emerged for the PD group reacting with more eosinophils (β=5.03, 
95% CIs = -0.73–10.79). The presence of PD conferred no effect on neutrophils (β=-11.72, 95% 
CIs = -34.64–11.18) or macrophages (β=0.10, 95% CIs = -22.63–22.82). Analyses did not reveal 
a significant effect of PD on immune reactivity to CO2. 
Conclusions 
PD appears to influence immunological responses in asthmatics by decreasing the proportion of 
sputum lymphocytes following a methacholine challenge, but does not seem to alter the 
immunological responses to CO2 inhalation. Additional studies are indicated to characterize the 
immunological interrelations between these conditions; these discoveries could allow clinicians 
to select more targeted treatments for this population. 
 







Asthma is a complex respiratory disease characterized by reversible and intermittent 
airway narrowing, obstruction, and hyper-reactivity. Despite the advancements in the 
understanding and treatment of asthma, the disease affects over 8% of Canadians aged 12 and 
above (1) and many patients struggle to control their asthma symptoms (15). More than half of 
Canadian asthmatics reported having had an asthma attack or having been affected in their daily 
activities by asthma symptoms in the past 12 months, despite over 65% of these people reporting 
taking medication (14). 
Airway obstruction in asthma is the result of inflammation (2) which, when untreated, 
causes the smooth muscles that surround the airway to become sensitive and contract 
(bronchoconstriction). Asthma is an immunological disease and the chronicity of asthma is 
believed to be associated with an altered humoural immune system response. Signaling 
molecules known as cytokines play an important role in orchestrating, perpetuating, and 
amplifying inflammation in asthma (58, 59). More specifically, the cytokines interleukin(IL)-5 
and eotaxin recruit (58), strengthen (7, 10), and activate (60) eosinophils, the white blood cells 
(leukocytes) implicated in allergic asthma (7, 58) whose excessive presence in the lung are 
considered one of the hallmarks of allergic asthma (10). Eosinophils release their cytotoxic 
granules (11), which contribute to the destruction of the airway epithelium that is typical in 
asthma (12). In addition, eosinophils release T helper type 2 (Th2)-promoting and Th1-
suppressing cytokines, such as IL-5 (7, 13), thus further propagating inflammation in a positive 
feedback loop style. 
Stress and anxiety can have a significant negative influence on respiratory functioning 
and quality of life in individuals with asthma (22, 24, 36), and psychiatric disorders are 
overrepresented in the asthmatic population (16-21). Psychological factors may be exerting a 
negative effect through already-existing immunological processes in asthma. The few studies 
available in the asthma literature depict a model where an interaction between acute stress and 
chronic stress mediates immunological pathways (25, 26, 28, 61). Physiologically, acute stress 
activates the immune system in individuals to protect them during this period of stress. 
Meanwhile, chronic stress, while typically associated to immunosuppression, may be instead 
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driving and amplifying inflammation in individuals affected by inflammatory conditions such as 
asthma (25). The model would suggest that the occurrence of an acute stress may aggravate the 
already existing inflammation-amplifying processes associated with chronic stress; in other 
words, sudden anxiety may exacerbate the already-existing immune responses present in asthma, 
thus worsening the condition or producing negative effects. Despite the emergence of this model, 
very little research discussing the immune system’s role in asthma and psychological distress is 
available (29).  
Panic disorder (PD) is of particular interest in asthma: studies report that PD is up to 12 
times more prevalent in asthmatics than in the general population (19, 35), and  is associated 
with worse outcomes in asthma, including a lower quality of life, a greater use of short-acting 
asthma medication, and more visits to primary care physicians (36). PD is characterized by 
sudden, unprovoked, and recurrent panic attacks (34), which are episodes of intense fear that are 
associated with a number of cognitive and physical symptoms. PD may influence asthma 
negatively by virtue of panic attacks having many similar symptoms to asthma attacks (shortness 
of breath, sudden anxiety, sensations of being smothered, and fear of losing control); this overlap 
leads patients and medical professionals to occasionally misinterpret the nature of the crisis, 
which may delay appropriate treatment. Panic attacks could, however, also be triggering asthma 
attacks through physiological pathways (37). In fact, the unanticipated panic attacks that occur 
within the context of PD make it fit well into our current acute and chronic stress model: could 
panic attacks (i.e.: an acute stressor) make asthma worse through amplified immune reactivity 
brought on by an anxiety disorder such as PD (i.e., a chronic stress)?  
This line of reasoning warrants an examination of the PD-related immunology research. 
Unfortunately, immunity in PD has not been investigated within the context of asthma, and only 
scant, contradictory literature is available on immunological abnormalities in PD for non-
asthmatics (40-42). It appears nonetheless that both the presence of PD and panic attacks are 
associated with poorer immune profiles. One study reported that PD patients had lower Th1 
cytokines(41). Given the antagonistic relationship between Th1 and Th2 products, these results 
would suggest that PD patients may tend to have a Th2 immune profile (similar to that which 
exists in asthma); this would entail the elevated presence of IL-5, which propagates the presence 
of eosinophils in the asthmatic lung. Furthermore, another study also reported that eotaxin, one 
of the principal recruiters of eosinophils into the lung in asthma, was significantly more 
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detectable at rest in patients with PD (42) than in healthy controls. Though these studies report 
blood serum markers, the findings are enough to suggest that the effects of PD may have an 
influence on the pathological processes in asthma, and that this possible influence is worthy of 
preliminary investigation using methods that are more pertinent in the context of asthma. 
The objective of this study was to collect pilot data to examine whether PD can alter an 
asthmatic individual’s immunological reactivity during relevant acute stressors. More 
specifically, we were interested in knowing 1) Do participants with asthma and PD have a 
different immunological response to a methacholine challenge (asthma attack simulation) 
compared to asthmatics without PD, and 2) do participants with asthma and PD have a different 
immunological reaction to a simulated panic attack compared to asthmatics without PD? 
Following the acute and chronic stress model cited above, we anticipated that the occurrence of 
an acute stressor (asthma attack or panic attack) in the presence of a chronic stressor (PD) would 
exacerbate the immune processes present in a chronic inflammatory disease (asthma). Given the 
role of eosinophils in propagating asthma, we hypothesized that, compared to asthmatics without 





This study was a component of a larger study seeking to investigate the impact of stress 
on cardiac and bronchial reactivity in asthmatics. The data collection took place over three 
separate visits. There were on average 27 days between visits, and visits were at least five days 
and at most 77 days apart. For a flowchart of the testing protocol (described in greater detail 
below), see Figure 1. The extended methodology is available in Appendix B. 
 
Recruitment 
Eleven asthmatic patients were recruited from the Hôpital du Sacré-Coeur de Montréal 
(HSCM). Participants were eligible to participate in the study if they were 18 years of age or 
older, had an objectively confirmed physician-diagnosis of asthma, if they spoke English or 
French, if they were current non-smokers, and if they were not suffering from a more severe 
comorbid condition such as cancer or cardiovascular disease. Participants completed the Primary 
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Care Evaluation of Mental Disorders to screen for the presence or absence of PD. Prior to the 
first visit, eligible patients underwent a semi-structured psychiatric interview called the Anxiety 
Disorders Interview Schedule-IV (ADIS-IV) (62-65), administered by a clinical psychology 
doctoral student over the phone, to confirm the presence or absence of PD and other comorbid 
psychiatric disorders. Participants who had a primary PD according to the ADIS-IV were 
included in the PD group, while those without any history of psychiatric disorders were included 
in the control (non-PD) group.  
 
Testing Protocol 
This project was approved by the Human Ethics Committee at the HSCM. Patients 
coming in for the first visit signed a consent form. Consenting participants completed 
sociodemographic and medical history questionnaires, then underwent a methacholine inhalation 
challenge; this test is the diagnostic test for asthma which causes an asthma-like attack by 
inducing bronchoconstriction, and is used to classify asthma severity (i.e. a patient experiencing 
a 20% drop in forced expiratory volume in one second [FEV1] to lower doses of methacholine 
have more severe asthma). At the end of the test, participants were then given salbutamol 
(Ventolin) to reverse the airway narrowing, and then underwent an induced sputum test 15 
minutes later to collect immunological data (leukocytes). On the second visit, participants 
underwent a 35% carbon dioxide (CO2) inhalation challenge, which reliably induces a simulated 
panic attack. Following this challenge, participants once again underwent a sputum induction, 
waiting a total of one hour between the first onset of symptoms following an inhalation and the 
start of the sputum induction. Participants were given the option to participate on a third and 
final day of testing, where they underwent only an induced sputum test. The data collected on 




All spirometric tests (forced vital capacity, FEV1) were conducted following the American 
Thoracic Society guidelines (61). Participants inhaled increasing quantities of methacholine (0.0 
– 16mg/mL). The test ended when participants experienced a 20% drop in FEV1 in response to 
the methacholine inhalation, and participants were included if they had a 20% drop in FEV1 in  
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Day 3: Baseline (No Challenge) 
 
 
Figure 1.  Flowchart of the testing protocol. 
CO2 = Carbon dioxide; Comp. Air = Compressed air. 
 
reaction to a dose of methacholine ≤ 16mg/mL (61). We used DSM-IV criteria and the Acute 
Panic Inventory (API) (66) to determine if participants had a panic attack during the challenge. 
 
CO2 Inhalation Challenge 
The use of a single vital capacity inhalation of a 35% CO2 and 65% oxygen gas mixture, 
which is held for a few seconds before being exhaled (53), reliably induces a simulated panic 
attack, allowing researchers to circumvent the difficulty of studying unanticipated PD-related 
panic attacks. Inhaling CO2-rich air reliably induces panic attacks in about 80% of PD patients 
and 15% of controls (49, 67, 68). Compared to other panic induction challenges, panic induced 
by CO2 inhalation is also similar to naturally occurring panic (52, 53) and CO2 has been shown 
to be one of the strongest panicogenic agents (50, 51).  



































For this challenge, participants inhaled either one vital capacity inhalation of regular air 
(placebo) or one vital capacity of oxygen-balanced CO2-rich air (delivered in randomized order). 
After a 30 minute period of seated rest to allow the participants’ respiratory and cardiac 
measures to return to baseline, participants inhaled a vital capacity of the other gas. Both the 
participants and the researcher conducting the panic attack assessment following both inhalations 
were blind as to which gas was being administered, and we used DSM-IV criteria and the API 
(66) to determine if participants had a panic attack.  
 
Sputum Induction and Processing 
Sputum inductions were conducted at the end of each challenge day and followed the 
hypertonic saline inhalation procedure detailed by Pin et al. (69). Before starting the procedure, 
participants inhaled 200μg salbutamol to prevent any bronchoconstriction that might result from 
the sputum induction process. After the samples were collected in a sterile container, the 
expectorate was analysed for proportions of neutrophils, eosinophils, monocytes/macrophages, 
lymphocytes, and bronchial epithelial cells present in the sputum. Sputum was processed using 
standard clinical practices (70), then stained using Wright’s stain, which allowed the 
visualization of the leukocytes of interest. Relative levels of leukocytes were generated as 
percentages following cell counts performed on 400 non-squamous cells, with the exception of 
one methacholine day sample from the PD group and one CO2 day sample from the non-PD 
group, which had cell counts of 300 and 344, respectively. Samples had a cell viability greater 
than 50% and squamous cell contamination less than 20%. 
 
Data Management and Statistical Analyses 
We used an ANCOVA-based general linear model to evaluate whether group (PD, no 
PD) was associated with different methacholine responses for relative levels of sputum 
neutrophils, eosinophils, macrophages, and lymphocytes. For our second analysis, the same 
analytical plan was used replacing methacholine responses with simulated panic responses. All 
analyses included age, sex, inhaled corticosteroid (ICS) medication dose, and the baseline level 
(visit 3) of the dependent variable as a-priori defined covariates due to their influence on the 
outcomes. The β value for these statistical tests represents the slope of the regression line; a 
negative β indicates that the non-PD group had a higher proportion, while a positive β indicates 
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the opposite. The value of the β represents how much higher the proportion was in one group 
than the other.  
Given the small sample size and exploratory nature of the study, multiple tests were not 
corrected for. Missing data was handled using Rubin’s multiple imputation method (71) and 
following Harrell’s guidelines (72), which created twenty parallel datasets and produced one 
combined statistic per outcome measure.  
Given the lack of available data in the literature (see above), power and sample size 
analyses could not be calculated for the present study. No mean and standard deviation 
values have been reported previously (required to calculate a sample size (73)) for our outcome 
measures in the conditions relevant to our study, e.g., in asthmatics with and without PD, at 
baseline, following a methacholine challenge, and following a CO2 inhalation challenge. Data 
was collected for 11 patients; this number was determined on the basis of the time and resources 




Of the 11 asthmatic participants who underwent the testing protocol, seven had PD and 
four did not have PD. Six participants had complete data including all challenge day and 
covariate data. Nine patients of 11 agreed to take part in the optional third day of testing to 
collect baseline immunological sputum data. The mean age of the participants was 47 (±16) 
years, and the sample contained more female (n=9) than male participants (n=2). As seen in 
Table 1, there were no significant differences between the two groups (PD or non-PD) for any of 
the demographic variables.  
Three of the seven PD participants had a panic attack in response to the methacholine, 
compared to none of the four non-PD participants. All seven PD participants had a panic attack 
in response to the CO2 inhalation challenge, while only one of the four non-PD participants did. 
 
Objective 1: Methacholine Challenge Immune Reactivity 
After adjusting for covariates, the analyses demonstrated that the presence of PD had an effect on 
the proportions of leukocytes in post-methacholine sputum: lymphocytes occupied on average 




-0.75, 95% CIs = -1.30 – -0.20, p = .007). In addition, a trend emerged for sputum eosinophils, 
which occupied 5% more of the total leukocyte population in the PD group compared to the non-
PD group (β = 5.03, 95% CIs = -0.73 – 10.79, p = .087). PD did not appear to influence the 
proportions of sputum neutrophils (β = -11.72, 95% CIs = -34.64 – 11.18, p = .31) or 
macrophages (β = 0.10, 95% CIs = -22.63 – 22.82, p = .99). The covariate-adjusted and imputed 
post-methacholine findings are reported in Table 2. The unadjusted post-methacholine means are 
reported in Appendix C.  
 
TABLE 2.  Influence of Panic Disorder on Sputum Composition in 
Asthmatics following the Methacholine Challenge 
Marker (Mean) PD Non-PD 
% Neutrophils 45.0 56.8 
% Eosinophils 8.6 3.9 
% Macrophages 33.8 34.2 
% Lymphocytes 0.2 0.9 
Covariates included age, sex, ICS dose, and baseline proportion of the leukocyte being evaluated. 
 
TABLE 1.  Demographic Characteristics of Patients with and without PD 
Mean (SD) PD  Non-PD Missing Data F Value P 
n 7 4 - - - 
Age, (years) 43 (16) 55 (15) 0 1.34 .28 
Sex (% male [n])  29 [2] 0 [0] 0 1.31 .28 
BMI (kg/m
2
)  28.6 (8.8) 30.0 (5.5) 0 0.08 .78 
% Predicted FEV1 (Baseline) 93.1 (17.8) 88.6 (8.6) 0 0.22 .65 
PC20 (mg/mL*) 0.5 (0.06 – 6.33) 0.6 (0.09 – 3.01) 0 0.03 .87 
ICS Dose (μg**) 292 (233) 208 (72) 2 0.35 .58 
      
% Neutrophils (Baseline)  23.0 (17.4) 27.5 (12.4) 5 0.10 .77 
% Eosinophils (Baseline) 0.7 (0.7) 6.4 (9.0) 5 2.09 .22 
% Macrophages (Baseline) 54.9 (28.0) 62.4 (20.7) 5 0.11 .76 
% Lymphocytes (Baseline) 0.3 (0.2) 0.6 (0.9) 5 0.83 .41 
n = number; SD = standard deviation; BMI = body mass index; FEV1 = forced expiratory volume in one second; PC20 = 
concentration of methacholine required to cause a 20% drop in FEV1; ICS = inhaled corticosteroid. 
* Reported as Geometric mean (95% Confidence Intervals) 
** Fluticasone equivalent 
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Objective 2: CO2 Challenge Reactivity 
After adjusting for covariates, the analyses demonstrated that the presence of PD did not 
impact the proportions of sputum neutrophils (β = 31.25, 95% CIs = -9.91 – 72.41, p = .14), 
eosinophils (β = -9.78, 95% CIs = -49.50 – 29.95, p = .63), macrophages (β = -5.96, 95% CIs = -
32.55 – 20.63, p = .66), or lymphocytes (β = -0.22, 95% CIs = -2.06 – 1.63, p = .82) in the 
participants’ sputum following the CO2 inhalation challenge. The findings are reported in Table 
3. The covariate-adjusted and imputed post-CO2 findings are reported in Table 3. The unadjusted 
post-CO2 means are reported in Appendix C. 
 
TABLE 3.  Influence of Panic Disorder on Sputum Composition in 
Asthmatics following the CO2 Inhalation Challenge 
Marker (Mean) PD Non-PD 
% Neutrophils 47.4  18.1 
% Eosinophils 7.4 22.7 
% Macrophages 38.1 45.9 
% Lymphocytes 0.5 0.7 
Covariates included age, sex, ICS dose, and baseline proportion of the leukocyte being evaluated. 
 
DISCUSSION 
 To our knowledge, this was the first study to assess the role of inflammation in acute-
stress responses in patients with asthma and PD, two highly comorbid conditions. PD appears to 
influence immune reactivity in asthmatics following the methacholine challenge. Unexpectedly, 
lymphocytes were significantly less present in PD group sputum following the challenge. 
Lymphocytes are a type of leukocyte, some of whose subsets (such as T cells and B cells) are 
implicated in the pathogenesis and propagation of asthma (7). Given the nature of some subsets 
of lymphocytes being pro-inflammatory and others anti-inflammatory (such as the Th1 and Th2 
cells described above), the nature of this decrease as beneficial or detrimental in the asthma 
process depends heavily on which subset of lymphocytes were found in the sample. 
Unfortunately, the Wright’s stain used to identify cells does not give us additional information 
about subsets of lymphocytes present in sputum (70).  
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Though PD did not significantly alter the proportion of sputum eosinophils, a trend did 
emerge, and the PD group appeared to have higher eosinophils in response to the challenge than 
the non-PD group, which is consistent with our hypotheses. Recent trends in the diagnosis of 
asthma attempt to qualify asthma according to their inflammatory phenotype. Some asthma 
phenotypes include eosinophilic asthma, where ≥ 3% of the sputum cells are eosinophils, and 
neutrophilic asthma (neutrophils ≥ 76%) (74, 75). Our finding appears to indicate that PD 
participants tend to have an eosinophilic response to the methacholine challenge. A closer 
examination of our methacholine reactivity data revealed that six of the PD group participants 
were eosinophilic asthmatics (six samples available of seven), while none of the non-PD group 
participants were eosinophilic asthmatics (two samples available of four). This may corroborate 
the findings in the PD-related immunology research, which suggested that a Th2 cytokine profile 
may be present in PD patients (41, 42). This raises an interesting question about the nature of 
causality; unfortunately, it is impossible to determine with this data if eosinophilic reactivity in 
asthma predisposes an individual to the effects of PD, or if PD alters the pattern of 
immunological reactivity in asthma.  
The data above also indicate that the presence of PD does not confer a statistically 
significant effect on immunological reactivity to the CO2 inhalation challenge. This would 
indicate that both the asthmatics with and without PD are reacting immunologically in the same 
way. A simple examination of the results illustrates, however, that despite the small sample size, 
there is a great deal of difference in the sputum leukocyte profiles, which may be clinically 
meaningful. It appears that the cytokine profiles produced following the CO2-induced panic 
attack are the reverse of those produced following the methacholine-triggered asthma attack, 
with the exception of lymphocyte proportions. One interpretation of these data might suggest that 
panic might have a protective effect in asthma; surprisingly, this notion has been documented in 
bronchial reactivity: Lehrer and Carr reported in 1996 that asthmatics with PD had significantly 
lower levels of airway impedance (as measured by forced oscillation) than asthmatics without 
PD (76). 
The fact that both acute stress challenges produced different outcomes raises the question 
of the nature of both challenges; it has been demonstrated that different stressor types have 
different physiological effects in asthma (77). Further analysis of the relative sympathetic and 
parasympathetic patterns in responses to both simulated asthma attacks and panic attacks may 
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help explain the difference in reactivity in a similar manner to the differences seen between 
active and passive stressors (77). Of course, the wide variability of the data, which may also 
indicate that panic may be a more potent immunological trigger for some rather than for others, 
and the lack of statistical significance, means that great caution should be used in making any 
interpretations about these data. 
Only one of four non-PD asthmatics experienced a panic attack compared to all seven 
asthmatics with PD in response to the 35% CO2 inhalation challenge. These differences in panic 
attack reactivity to the CO2 challenge seems to be supported in an article by Fleet and 
colleagues, who reported that, in patients with coronary artery disease, those with PD reacted 
significantly more to the challenge than those who did not have PD (78). The fact that less than 
half of the non-PD group experienced a panic attack may have affected the results: a difference 
might not have emerged because the participants in both groups did not all react with a panic 
attack. This same circumstance may have also affected our post-methacholine values, where 
three PD participants of seven (but none of the non-PD participants) reacted to the methacholine 
with a panic attack. We conducted secondary analyses (ANOVA-like GLMs) using unadjusted 
and non-imputed data to determine how having a panic attack during the challenges affected 
reactivity in the presence and absence of PD. For the post-methacholine data, the lymphocyte 
results were maintained: those individuals who had PD and experienced a panic attack (3 of 6) 
had a lower proportion of lymphocytes than the non-PD group, where none reacted with a panic 
attack. Furthermore, the PD participants who had experienced a panic attack also had a lower 
proportion of lymphocytes than the PD participants who did not experience a panic attack (3 of 
6). For the CO2 results, the same statistical approach revealed that the non-PD group participant 
who experienced a panic attack had a higher proportion of eosinophils than both the non-PD 
group who had no panic attack, as well as the PD group (all of which had a panic attack). While 
this finding might suggest that the panic attack might have a more profound impact than the 
presence of PD, it is important to recall that this comparison was made with only a single 
participant who appeared to have a very pronounced eosinophilic reactivity, even compared to 
the other participants in the study. The means and additional analyses can be found in Appendix 
D. These preliminary data support the idea that there may be an interaction between acute and 




 This study has some limitations, the most important of which is the already-mentioned 
small sample size. As with all underpowered studies, the true effects may not have been revealed 
by the analyses, and findings should be considered with caution. In addition, the sample of 11 
included only two men. While the inclusion of sex as a covariate may have accounted for sex 
differences (such as hormonal levels), the sample would arguably have benefited from additional 
male participants.  
 There was a great deal of variability in the time between visits across patients, which is 
not ideal. This was usually the result of scheduling conflict, but some participants felt that the 
temperature and humidity also affected their level of airway obstruction. In all cases where 
testing was conducted, however, all patients were stable and started with at least 80% of their 
percent predicted FEV1 as per the American Thoracic Society guidelines (61). In addition, 
patients were not tested on days where they felt sick because this would likely have biased the 
immunological results.  
Missing data was also a limitation: on the methacholine challenge day, three participants 
did not produce a sputum sample, while only one participant did not produce a sample on the 
CO2 inhalation day. For the baseline day assessment, five samples could not be collected: three 
participants could not expectorate and two others had declined to participate. Looking only at the 
numbers, one might speculate that the CO2 challenge may have contributed somewhat to the 
participants’ ability to expectorate or produce a sample; this line of thinking would corroborate 
the thought that CO2 inhalation could indeed present a physiological challenge for asthmatics. 
However, with approximately 27% missing data overall, 20 imputations were conducted to 
ensure that the imputation efficiency would be preserved (71).  
Finally, the true effects of PD may have been revealed had we evaluated certain immune 
cell markers rather than the leukocytes themselves. While the asthma literature regularly 
evaluates both sputum leukocyte and cytokines, the PD literature consists only of the evaluation 
of serum cytokines (40-42, 57). As a result, the evaluation of a number of cytokines and 
chemokines relevant in the pathophysiology of asthma may have been indicated. These markers 
would include IL-5 and eotaxin, which are important for shuttling eosinophils into the lungs (10), 
as well as IL-4, IL-12, IL-13, and IFN-γ, which might reflect the dominance of the Th2 profile 
over Th1. Though additional, more rigorous and comprehensive studies are necessary to confirm 
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these findings, the results presented here may nonetheless shed an important light on the possible 
mechanisms linking PD to worse outcomes in asthma. 
 
CONCLUSION 
Since the majority of the relatively few studies conducted on the topic have been 
correlational and have been limited to examining non-physiological outcomes, the mechanisms 
driving the relationship between psychological factors and worse asthma remain elusive. This 
study is the first to explore PD’s association to asthma from an immunological standpoint, and 
presents novel, preliminary data in the investigation of PD’s effect as a moderator of 
immunological reactivity in response to stress in asthma. The presence of PD appears to have an 
influence on immunological reactivity in asthmatics such that the proportion of sputum 
lymphocytes are decreased, and while it seems that PD does not alter the immunological 
reactivity to CO2 inhalation, additional, more rigorous and comprehensive studies may be 
indicated. Future studies in this domain should seek to investigate the immunological changes in 
asthmatics conferred by the presence of PD by looking more specifically at cytokine reactivity in 
an acute stress context. Accurately elucidating the mechanisms and interrelations between these 
two conditions may allow us to identify specific immunological markers common to both 
conditions, which may lead to the development of new therapeutics and treatment strategies, but 
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Diagnostic Criteria for Panic Disorder from the DSM-IV 
















Diagnostic Criteria for Panic Disorder from the DSM-IV (34) 
 
1) Recurrent unexpected panic attacks (see below) 
2) Persistent concern about having additional attacks, including worry about the 
implications of attack or its consequences 
3) Significant change in behavior as a result of the attacks 
 
Panic Attack: 
A discrete period of intense fear or discomfort in which four or more of the following 
symptoms develop abruptly and reach a peak within 10 minutes: 
 
(1) Palpitations or accelerated heart rate 
(2) Sweating 
(3) Trembling or shaking 
(4) Shortness of breath (dyspnea)  
(5) Choking 
(6)  Chest pain or discomfort 
(7)  Nausea or abdominal discomfort 
(8)  Feeling dizzy, unsteady, or faint 
(9)  Numbness or tingling sensations (paresthesias) 
(10) Chills or hot flashes 
(11) Derealization (feelings of unreality) or depersonalization (being detached from oneself) 
(12) Fear of losing control or going crazy 











































Eleven asthmatic patients were recruited from the asthma clinics at the Hôpital du Sacré-
Coeur de Montréal. Participants were considered eligible to participate in the study if they were 
18 years of age or older, had an objectively confirmed physician-diagnosis of asthma, if they 
spoke either English or French, if they were non-smokers, and if they were not suffering from a 
more severe comorbid condition such as cancer or cardiovascular disease. Participants completed 
the Primary Care Evaluation of Mental Disorders (PRIME-MD) to screen for the presence or 
absence of PD. Prior to the first visit, eligible patients underwent a semi-structured psychiatric 
interview called the Anxiety Disorders Interview Schedule-IV (ADIS-IV) (62), administered by 
a clinical psychology doctoral student over the phone, to reconfirm the presence or absence of 
PD and other comorbid anxiety disorders. The ADIS-IV, which rates anxiety disorder-related 
symptoms on a 0 – 8 Likert scale (63), has good psychometric properties (63, 64), with good 
inter-rater agreement for PD in terms of diagnostic reliability (κ=0.72) (65). 
 
General Protocol Parameters 
This study was a component of a larger study seeking to investigate the impact of stress 
on cardiac and bronchial reactivity in asthmatics. This project was approved by the Ethics 
Committee at the HSCM. The data collection takes place over three separate visits.  
All spirometric tests (forced vital capacity [FVC], forced expiratory volume in one 
second [FEV1]) were conducted following the American Thoracic Society guidelines (61). 
Percent predicted FEV1 values were obtained by comparing the recorded FEV1 values to 
predicted FEV1 values for patients under the age of 70 (79). 
 
Day 1: Methacholine Challenge 
Patients coming in for the first day signed a consent form. Consenting participants then 
completed sociodemographic and medical history questionnaires, and underwent a methacholine 
inhalation challenge, where they inhaled increasing quantities of methacholine, a histamine-like 
substance that causes bronchoconstriction. Each participant inhaled every increasing dose of 
nebulised methacholine for two minutes, starting with a diluent (0.0mg/mL methacholine), and 
followed by 0.03mg/mL, 0.06mg/mL, 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 1.0mg/mL, 
2.0mg/mL, 4.0mg/mL, 8.0mg/mL, and finally, 16.0mg/mL (this is the maximum dose that any 
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participant received). Participants were included in the study if they had mild to moderate 
asthma, defined by having had a 20% drop in FEV1 in reaction to a dose of methacholine ≤ 
16mg/mL (61). 
The test ended when participants experienced a 20% drop in FEV1 in response to the 
methacholine inhalation. Participants were then given salbutamol (Ventolin) to reverse the 
airway narrowing, and then underwent an induced sputum test, which served to collect 
immunological data (leukocytes). 
 
Day 2: Induced Panic Attack 
On the second day, participants underwent the 35% CO2 respiratory challenge, where 
they inhaled both one vital capacity inhalation of regular air (placebo) and one vital capacity of 
oxygen-balanced CO2-rich air, delivered in randomized order. We used DSM-IV criteria and the 
Acute Panic Inventory (API) (66) to determine if participants had a panic attack. (For a list of 
panic attack symptoms, see Appendix A.) The API is a checklist with 17 items, each ranked on a 
4-point scale from 0 (no symptom) to 3 (severe), that asks questions pertaining to panic attack 
symptoms, such as “Do you feel nauseous?” and “Do you feel faint?” Both the participants and 
the researcher conducting the panic attack assessment following both inhalations were blind as to 
which gas was being administered, and a 30 minute period followed the inhalation of each gas in 
order for the participants’ respiratory measures to return to baseline. Following this challenge, 
participants once again underwent a sputum induction, waiting a total of one hour between the 
first onset of symptoms following an inhalation and the start of the sputum induction.  
 
Day 3: Baseline 
On the third and final day, participants underwent only an induced sputum test. The data 
collected on this day served as baseline data. 
 
Sputum Induction 
Sputum inductions were conducted as per standard clinical procedures (69). Before 
starting the procedure, participants inhaled salbutamol (200μg) to prevent any 
bronchoconstriction that might result from the sputum induction process. Participants then 
inhaled increasing concentrations of vaporized hypertonic saline solution (3%, 4%, 5%) for 
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seven minutes each. Between each inhalation period, participants were instructed to blow their 
nose and rinse their mouth with water, then to expectorate into a sterile container.  
 
Inflammatory Markers 
The expectorate collected at the end of each testing day was analysed for immune cells. 
We were mainly interested in relative levels of leukocytes present in the sputum, including 
neutrophils, eosinophils, macrophages, and lymphocytes. The expectorate was processed by first 
separating the sputum samples from the saliva and placing these samples in a test tube. The 
sputum samples were then treated using dithiothreitol and placed on a test tube rocker for 15 
minutes. Following this period, the sample was resuspended with phosphate buffered saline 
(PBS) and then filtered through a nylon mesh. To determine the total cell count and cell viability, 
the cells were mixed with an equal amount of trypan blue and were counted under the 
microscope. To begin the process of identifying the cells and calculating cell proportions, the cell 
concentration was adjusted using PBS to obtain a concentration of 1.0 x 10
6
 cells per mL. To 
identify the cells, 60μL of the suspension was centrifuged at 450rpm for six minutes, and then 
stained using Wright’s stain (which allowed the visualization of eosinophils, neutrophils, 
lymphocytes, monocytes/macrophages, and bronchial epithelial cells).  
 
Remuneration 
For their participation in the project, participants had their hospital parking stubs and bus 
tickets refunded. In addition, participants were remunerated for the total amount of $120.00, 
consisting of $50.00 for the first day, $50.00 for the second day, and $20.00 for the third day. 
Participants who dropped out of the study or were deemed ineligible to participate were paid for 













































TABLE C1.  Influence of Panic Disorder on Sputum Composition in Asthmatics 
following the Methacholine Challenge using non-imputed data with no adjustment 
for covariates 
Marker (Mean, SD) PD Non-PD P 
N 6 2 - 
% Neutrophils 33.0 (26.2) 68.1 (3.7) .12 
% Eosinophils 9.9 (5.8) 1.4 (0.9) .099 
% Macrophages 43.7 (26.3) 26.3 (3.5) .41 
% Lymphocytes 0.2 (0.1) 0.9 (0.5) .013 




TABLE C2.  Influence of Panic Disorder on Sputum Composition in Asthmatics 
following the CO2 Inhalation Challenge using non-imputed data with no adjustment 
for covariates 
Marker (Mean, SD) PD Non-PD P 
N 7 3 - 
% Neutrophils 40.6 (28.2) 32.9 (27.2) .70 
% Eosinophils 5.4 (7.6) 26.5 (45.1) .23 
% Macrophages 42.1 (18.0) 35.3 (16.0) .59 
% Lymphocytes 0.8 (1.1) 0.2 (0.3) .40 























Secondary Analyses on the Influence of Panic Attacks on Immunological Reactivity in the 



















TABLE D1.  Influence of Panic Attacks on Sputum Composition in Asthmatics 
following the Methacholine Challenge using non-imputed data with no adjustment for 
covariates 
Mean (SD) Non-PD (No PA) PD (No PA) PD (PA) 
N 2 3 3 
% Neutrophils 68.1 (3.7) 45.5 (34.3) 20.5 (8.1) 
% Eosinophils 1.4 (0.9) 6.9 (1.5) 12.8 (7.5) 
% Macrophages 26.3 (3.5) 31.0 (33.0) 56.4 (12.3) 
% Lymphocytes 0.9 (0.5) 0.3 (0.0) 0.1 (0.1) 




TABLE D2.  Influence of Panic Attacks on Sputum Composition in Asthmatics 
following the CO2 Inhalation Challenge using non-imputed data with no adjustment 
for covariates 
Mean (SD) Non-PD (No PA) Non-PD (PA) PD (PA) 
N 2 1 7 
% Neutrophils 48.3 (7.0) 2.0 (-) 40.6 (28.2) 
% Eosinophils 0.5 (0.6) 78.5 (-) 5.4 (7.6) 
% Macrophages 44.5 (2.4)  17.0 (-) 42.1 (18.0) 
% Lymphocytes 0.3 (0.4) 0.0 (-) 0.8 (1.1) 
SD = Standard deviation; PA = Panic attack. 
 
 
 
 
 
